IDEXX Laboratories, Inc. logo
IDEXX Laboratories, Inc. (IDXX)
Compare

IDEXX Laboratories, Inc. (IDXX) PE Ratio: 42.69

Is IDEXX Laboratories, Inc.’s P/E ratio high or low?

IDEXX Laboratories, Inc.'s P/E ratio of 42.69 is 20% below its 5-year average of 53.54, near the low end of its 5-year range (33.84–90.63).

The P/E ratio for IDEXX Laboratories, Inc. (IDXX) is 42.69 as of Tuesday, June 9, 2026. It is below its 12-month average by 15.14% (50.31).

PE Ratio (42.69) = Close Price ($578.89) / Diluted TTM EPS ($13.56)

IDXX PE Ratio Chart

IDXX PE Ratio
42.69-10.93% 1Y
Zoom

IDXX Average PE Ratio Chart

IDXX Current vs Average PE Ratio Chart

IDXX PE Ratio Metrics

PE RATIO

42.69

PE RATIO AVG TTM

50.31

PE RATIO AVG 3Y

48.97

PE RATIO AVG 5Y

53.54

PE RATIO AVG 10Y

57.17

PE RATIO AVG 15Y

49.26

PE RATIO AVG 20Y

44.31

CURRENT VS TTM AVG

-15.14%

CURRENT VS 3Y AVG

-12.83%

CURRENT VS 5Y AVG

-20.27%

CURRENT VS 10Y AVG

-25.33%

CURRENT VS 15Y AVG

-13.33%

CURRENT VS 20Y AVG

-3.66%

IDXX Competitors' PE Ratio

NAMEMARKET CAPPE RATIOTTM3Y5Y
IDEXX Laboratories, Inc. (IDXX)42.6950.3148.9753.54
Humana Inc. (HUM)$43.60B38.8421.7921.2321.06
Agilent Technologies, Inc. (A)$38.26B27.2029.3529.8132.79
Zoetis Inc. (ZTS)$34.46B13.6322.1930.4935.47
Centene Corporation (CNC)$32.69BN/A9.3712.4922.33
IQVIA Holdings Inc. (IQV)$31.09B23.0825.9729.3338.55
DexCom, Inc. (DXCM)$30.17B33.4142.1371.74113.70
Biogen Inc. (BIIB)$29.39B21.3216.5018.4918.66
Regeneron Pharmaceuticals, Inc. (REGN)$63.48B15.0116.2820.8717.83
Veeva Systems Inc. (VEEV)$27.37B29.8947.2254.6966.93

P/E vs. its own history

At 42.7, P/E is in its normal range — richer than 53% of its 20-year range.

20-year low

8.5

median

41.3

20-year high

92.1

cheaperricher

P/E Comparison

Trailing P/E

42.7

Forward P/E

34.9

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$578.89

÷

Forward EPS (Est.)

$16.57

=

Forward P/E

34.94

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

IDEXX Laboratories, Inc. PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

IDEXX Laboratories, Inc. PE Ratio FAQ

What is the P/E ratio for IDEXX Laboratories, Inc. (IDXX)?
The P/E ratio for IDXX stock is 42.69.
Is IDEXX Laboratories, Inc.'s P/E ratio high or low?
IDEXX Laboratories, Inc.'s P/E ratio of 42.69 is 20% below its 5-year average of 53.54, near the low end of its 5-year range (33.84–90.63).
What is the TTM average P/E ratio for IDEXX Laboratories, Inc. (IDXX)?
The TTM average P/E ratio for IDXX stock is 50.31.
What is the 3Y average P/E ratio for IDEXX Laboratories, Inc. (IDXX)?
The 3Y average P/E ratio for IDXX stock is 48.97.
What is the 5Y average P/E ratio for IDEXX Laboratories, Inc. (IDXX)?
The 5Y average P/E ratio for IDXX stock is 53.54.
What is the 10Y average P/E ratio for IDEXX Laboratories, Inc. (IDXX)?
The 10Y average P/E ratio for IDXX stock is 57.17.
What is the 15Y average P/E ratio for IDEXX Laboratories, Inc. (IDXX)?
The 15Y average P/E ratio for IDXX stock is 49.26.
What is the 20Y average P/E ratio for IDEXX Laboratories, Inc. (IDXX)?
The 20Y average P/E ratio for IDXX stock is 44.31.

IDEXX Laboratories, Inc. PE Ratio History

DATEPE RATIO
2026-06-0942.69
2026-06-0841.38
2026-06-0541.46
2026-06-0441.65
2026-06-0341.35
2026-06-0240.62
2026-06-0141.80
2026-05-2941.56
2026-05-2841.89
2026-05-2740.63
2026-05-2641.09
2026-05-2241.25
2026-05-2140.79
2026-05-2040.82
2026-05-1940.30
2026-05-1840.25
2026-05-1539.00
2026-05-1439.30
2026-05-1338.99
2026-05-1239.37
2026-05-1139.23
2026-05-0841.31
2026-05-0742.20
2026-05-0642.72
2026-05-0541.52
2026-05-0443.08
2026-05-0143.42
2026-04-3042.91
2026-04-2942.36
2026-04-2843.48
2026-04-2743.99
2026-04-2443.30
2026-04-2342.92
2026-04-2244.25
2026-04-2143.54
2026-04-2044.61
2026-04-1745.08
2026-04-1643.61
2026-04-1544.43
2026-04-1444.69
2026-04-1343.92
2026-04-1043.08
2026-04-0944.74
2026-04-0845.28
2026-04-0743.98
2026-04-0644.18
2026-04-0243.58
2026-04-0143.20
2026-03-3142.99
2026-03-3042.62
2026-03-2742.72
2026-03-2643.86
2026-03-2544.05
2026-03-2443.63
2026-03-2344.26
2026-03-2044.17
2026-03-1944.36
2026-03-1844.16
2026-03-1744.91
2026-03-1644.86
2026-03-1343.90
2026-03-1243.70
2026-03-1145.95
2026-03-1045.82
2026-03-0946.71
2026-03-0646.55
2026-03-0547.35
2026-03-0449.63
2026-03-0348.63
2026-03-0248.71
2026-02-2750.25
2026-02-2650.55
2026-02-2550.30
2026-02-2449.67
2026-02-2347.68
2026-02-2048.64
2026-02-1950.02
2026-02-1850.35
2026-02-1749.66
2026-02-1349.91
2026-02-1248.95
2026-02-1151.45
2026-02-1051.27
2026-02-0950.74
2026-02-0651.12
2026-02-0551.04
2026-02-0450.99
2026-02-0350.16
2026-02-0250.72
2026-01-3053.17
2026-01-2953.66
2026-01-2854.54
2026-01-2755.10
2026-01-2655.34
2026-01-2355.02
2026-01-2254.80
2026-01-2155.23
2026-01-2054.40
2026-01-1656.73
2026-01-1556.47
2026-01-1456.34
2026-01-1356.62
2026-01-1257.48
2026-01-0956.57
2026-01-0856.49
2026-01-0756.67
2026-01-0656.05
2026-01-0554.10
2026-01-0253.13
2025-12-3153.65
2025-12-3054.11
2025-12-2954.55
2025-12-2654.60
2025-12-2454.57
2025-12-2354.11
2025-12-2255.68
2025-12-1955.54
2025-12-1855.28
2025-12-1755.16
2025-12-1654.97
2025-12-1555.56
2025-12-1255.84
2025-12-1156.11
2025-12-1055.66
2025-12-0955.44
2025-12-0856.04
2025-12-0556.63
2025-12-0456.90
2025-12-0357.57
2025-12-0258.11
2025-12-0157.81
2025-11-2859.70
2025-11-2659.95
2025-11-2560.80
2025-11-2459.65
2025-11-2157.57
2025-11-2054.67
2025-11-1955.28
2025-11-1853.15
2025-11-1753.05
2025-11-1454.71
2025-11-1355.63
2025-11-1256.59
2025-11-1156.50
2025-11-1056.27
2025-11-0756.18
2025-11-0656.60
2025-11-0557.11
2025-11-0457.27
2025-11-0357.33
2025-10-3152.42
2025-10-3052.33
2025-10-2952.26
2025-10-2852.82
2025-10-2753.91
2025-10-2453.36
2025-10-2353.17
2025-10-2252.77
2025-10-2153.05
2025-10-2053.57
2025-10-1752.91
2025-10-1653.07
2025-10-1553.22
2025-10-1453.03
2025-10-1352.73
2025-10-1051.30
2025-10-0952.35
2025-10-0852.45
2025-10-0752.23
2025-10-0652.27
2025-10-0352.56
2025-10-0252.78
2025-10-0151.63
2025-09-3053.20
2025-09-2952.50
2025-09-2652.64
2025-09-2551.47
2025-09-2452.22
2025-09-2353.99
2025-09-2253.63
2025-09-1954.63
2025-09-1854.58
2025-09-1753.36
2025-09-1653.76
2025-09-1553.62
2025-09-1253.38
2025-09-1153.72
2025-09-1053.12
2025-09-0954.59
2025-09-0854.36
2025-09-0553.54
2025-09-0453.33
2025-09-0352.79
2025-09-0253.24
2025-08-2953.88
2025-08-2853.87
2025-08-2753.36
2025-08-2653.43
2025-08-2553.40
2025-08-2253.75
2025-08-2152.71
2025-08-2053.28
2025-08-1953.01
2025-08-1853.11
2025-08-1554.19
2025-08-1454.45
2025-08-1355.28
2025-08-1254.31
2025-08-1154.30
2025-08-0854.79
2025-08-0754.13
2025-08-0651.97
2025-08-0553.45
2025-08-0456.85
2025-08-0149.50
2025-07-3149.38
2025-07-3052.87
2025-07-2952.96
2025-07-2852.36
2025-07-2552.24
2025-07-2450.83
2025-07-2349.97
2025-07-2249.17
2025-07-2148.14
2025-07-1847.56
2025-07-1747.94
2025-07-1648.11
2025-07-1548.67
2025-07-1449.11
2025-07-1149.29
2025-07-1050.01
2025-07-0949.97
2025-07-0849.80
2025-07-0750.42
2025-07-0350.56
2025-07-0250.16
2025-07-0150.15
2025-06-3049.57
2025-06-2749.11
2025-06-2648.78
2025-06-2549.02
2025-06-2449.03
2025-06-2348.49
2025-06-2048.42
2025-06-1848.05
2025-06-1748.11
2025-06-1648.87
2025-06-1348.31
2025-06-1248.70
2025-06-1148.45
2025-06-1048.61
2025-06-0947.93
2025-06-0648.51
2025-06-0548.26
2025-06-0448.51
2025-06-0348.60
2025-06-0247.58
2025-05-3047.45
2025-05-2947.65
2025-05-2847.54

Showing the most recent 260 of 5,031 data points. The chart above shows the full history.

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.

Westbrook, ME
11,000 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Jonathan J. Mazelsky